Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
s24q10PXcqFYL782
